Global Carbapenem Based Antibiotics Market Overview 2024, Forecast To 2033
8 Mar, 2024
The carbapenem-based antibiotics market (7) has witnessed strong growth, increasing from $4.43 billion in 2023 to $4.66 billion in 2024, with a CAGR of 5.1%. This growth is attributed to epidemics, chronic diseases, and healthcare infrastructure growth. Future growth is projected, with the market expected to reach $5.71 billion by 2028, growing at a CAGR of 5.2%. Factors such as hospital-acquired infections, emergence of multi-drug resistant strains, and the aging population contribute to this growth. Key trends include supply chain resilience, alternative treatment development, shift towards outpatient settings, awareness on antimicrobial stewardship, and precision medicine approaches.
Global Carbapenem Based Antibiotics Market Key Driver
The increasing incidence of bacterial infections is expected to propel the growth of the carbapenem-based antibiotics market. Carbapenem-based antibiotics are essential for treating severe or multidrug-resistant bacterial infections. For instance, in England, the UK Health Security Agency reported a 2.2% increase in antibiotic-resistant severe infections in 2021. Hence, the rising incidence of bacterial infections is fueling the growth of the carbapenem-based antibiotics market.
Get A Free Sample Of The Global Carbapenem Based Antibiotics Market ReportGlobal Carbapenem Based Antibiotics Market Segments
The carbapenem-based antibiotics market covered in this report is segmented –
1) Type:Meropenem, Imipenem, Doripenem, Tebipenem, Other Types
2) Indication:Intra-abdominal Infections, Urinary Tract Infections, Pneumonia, Bacterial Meningitis, Skin and Skin Structure Infections, Acute Pelvic Infections, Prophylaxis of Surgical Site Infection, Respiratory Tract Infections, Gynecological Infections, Other Indications
3) Distribution Channel:Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
North America was the largest region in the Carbapenem-Based Antibiotics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Major Carbapenem Based Antibiotics Industry Players
Pfizer Inc.; Merck & Co. Inc.; Saint-Gobain S.A.; Fresenius Kabi LLC; GlaxoSmithKline Plc; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; AstraZeneca plc; Meiji Holdings Co. Ltd.; Sandoz International GmbH; Sumitomo Dainippon Pharma Co. Ltd.; Shionogi & Co Ltd.; Aurobindo Pharma Ltd.; Acurx Pharmaceuticals LLC; Daewoong Pharmaceutical Co. Ltd.; CeramTec GmbH; ACS Dobfar S.p.A; JW Pharmaceutical Corp; Centrient Pharmaceuticals Co; Spero Therapeutics Inc.; Kopran Limited; Savior Lifetec Corporation; Amedica Corporation; Flagship Biotech International Pvt. Ltd.; Iterum Therapeutics plc; Cam Carbapenem-based antibiotics BV; Intelicure Lifesciences; Ikeda Corporation
Get The Full Global Carbapenem Based Antibiotics Market Report
Carbapenem Based Antibiotics Market Overview
Carbapenem-based antibiotics are a class of broad-spectrum antibiotics that are highly effective against many bacterial infections. Carbapenem antibiotics are commonly used to treat severe infections caused by gram-positive and gram-negative bacteria, including some strains resistant to other antibiotics.